Ascidian Therapeutics’ Post

Gene&Cell Therapy >> AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Is this the big turnaround year for biotech investment? If you missed John Carroll’s panel discussion on the topic, you can now watch the video on-demand here. AbbVie’s next CEO After months of speculation, AbbVie announced CEO Richard Gonzalez will hand the CEO post to president and COO Robert Michael on July 1. As the Chicago-area Big Pharma progresses through its transition from Humira with expectations of major revenue loss, Michael will be tasked with building a new empire, in part on two recently-inked acquisitions. $100B club refresh For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold — joining about 15 other drugmakers that count as the industry’s biggest and include other giants like Johnson & Johnson, Merck, and Novartis. Andrew Dunn takes a look at what the induction of these new heavyweights says about the industry. Top 100 VCs, 2023 2023 marks one of those years in life sciences when venture capital spent a lot of time looking for ways to preserve cash runways and finding bridges to human data. Endpoints’ John Carroll and DealForma chief Chris Dokomajilar break it all down with this year’s top 100 list of biotech investors, complete with analysis of trends regarding rounds, therapeutic areas and stages. More hope for CAR-T in autoimmune Just as new details from the first 15 autoimmune disease patients treated with CAR-T therapy added enthusiasm to the idea, Galapagos said it will pull out of the field, which it says is “very crowded.” As part of the decision, it will drop plans for a trial in systemic lupus erythematosus. Proteomics reinvigorated Once a scientific backwater, protein research has seen a surge of activity in recent months, attracting billion-dollar deals and high-profile publications. Jared Whitlock digs into how better instruments have let researchers tap the proteome to develop new tests and medicines, as well as the challenges in scaling the technology. R&D * Alnylam’s surprise change to the analysis plan for one of this year’s most anticipated clinical trial readouts set off a flurry of questions about the future of the company’s ATTR franchise and the outlook of its upcoming results. In an interview, CEO Yvonne Greenstreet told Lei Lei Wu the changes are a reflection that “we really are playing to win.” * NodThera is moving its NLRP3 inhibitors into the clinic after preclinical data showed it reversed obesity and inflammation in mice in a study that compared it against Novo… #lucidquest #genetherapy #celltherapy

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Is this the big turnaround year for biotech investment? If you missed John Carroll’s panel discussion on the topic, you can now watch the video on-demand here. AbbVie’s next CEO After months of speculation, AbbVie announced CEO Richard Gonzalez will hand the CEO post to president and COO Robert Michael on July 1. As the Chicago-area Big Pharma progresses through its transition from Humira with expectations of major revenue loss, Michael will be tasked with building a new empire, in part on two recently-inked acquisitions. $100B club refresh For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold — joining about 15 other drugmakers that count as the industry’s biggest and include other giants like Johnson & Johnson, Merck, and Novartis. Andrew Dunn takes a look at what the induction of these new heavyweights says about the industry. Top 100 VCs, 2023 2023 marks one of those years in life sciences when venture capital spent a lot of time looking for ways to preserve cash runways and finding bridges to human data. Endpoints’ John Carroll and DealForma chief Chris Dokomajilar break it all down with this year’s top 100 list of biotech investors, complete with analysis of trends regarding rounds, therapeutic areas and stages. More hope for CAR-T in autoimmune Just as new details from the first 15 autoimmune disease patients treated with CAR-T therapy added enthusiasm to the idea, Galapagos said it will pull out of the field, which it says is “very crowded.” As part of the decision, it will drop plans for a trial in systemic lupus erythematosus. Proteomics reinvigorated Once a scientific backwater, protein research has seen a surge of activity in recent months, attracting billion-dollar deals and high-profile publications. Jared Whitlock digs into how better instruments have let researchers tap the proteome to develop new tests and medicines, as well as the challenges in scaling the technology. R&D * Alnylam’s surprise change to the analysis plan for one of this year’s most anticipated clinical trial readouts set off a flurry of questions about the future of the company’s ATTR franchise and the outlook of its upcoming results. In an interview, CEO Yvonne Greenstreet told Lei Lei Wu the changes are a reflection that “we really are playing to win.” * NodThera is moving its NLRP3 inhibitors into the clinic after preclinical data showed it reversed obesity and… #lucidquest #genetherapy #celltherapy

Looking very much forward to hear the thoughts of the participants on digital endpoints in clinical studies. 👩🔬 #cosinuss #rpm #remotepatientmonitoring #clinicalstudies #pharma #biotech #digitalbiomarkers #digitalhealth #vitalsigns

Are you interested in ADCs with payloads beyond traditional cytotoxics and formats beyond mAbs? The 3rd Next-Generation Conjugates Summit will showcase developments in antibody-oligonucleotide, fragment-drug, bispecific-drug, antibody-steroid conjugates and other novel forms of ADCs as 𝐭𝐡𝐞 𝐨𝐧𝐥𝐲 𝐞𝐯𝐞𝐧𝐭 𝐝𝐞𝐝𝐢𝐜𝐚𝐭𝐞𝐝 𝐭𝐨 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐧𝐨𝐯𝐞𝐥 𝐩𝐚𝐲𝐥𝐨𝐚𝐝 𝐚𝐧𝐝 𝐟𝐨𝐫𝐦𝐚𝐭 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞 𝐝𝐞𝐬𝐢𝐠𝐧, 𝐞𝐬𝐭𝐚𝐛𝐥𝐢𝐬𝐡𝐢𝐧𝐠 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧, 𝐚𝐧𝐝 𝐬𝐭𝐫𝐞𝐚𝐦𝐥𝐢𝐧𝐢𝐧𝐠 𝐂𝐌𝐂 𝐭𝐨 𝐞𝐱𝐩𝐚𝐧𝐝 𝐭𝐡𝐞 𝐭𝐨𝐨𝐥𝐤𝐢𝐭 𝐨𝐟 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞 𝐝𝐫𝐮𝐠 𝐝𝐞𝐬𝐢𝐠𝐧 𝐚𝐧𝐝 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭. Learn from Dyne Therapeutics sharing their FORCE Platform to deliver transformative antibody-oligonucleotide conjugates for Mytonic Dystrophy 1, hear Theratechnologies Inc. discuss how their Peptide Drug Conjugate has rapid internalization and improved tumor penetration compared to traditional ADCs, AstraZeneca explore the design and preclinical activity of a Bispecific EGFR-MET targeted ADC, plus insights from another 30+ industry leading speakers. 𝐓𝐡𝐢𝐬 𝐰𝐞𝐞𝐤 𝐢𝐬 𝐚𝐥𝐬𝐨 𝐭𝐡𝐞 𝐥𝐚𝐬𝐭 𝐜𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐬𝐚𝐯𝐞 𝐨𝐧 𝐲𝐨𝐮𝐫 𝐫𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐬𝐭 𝐛𝐞𝐟𝐨𝐫𝐞 𝐭𝐡𝐞 𝐞𝐧𝐝 𝐨𝐟 𝟐𝟎𝟐𝟑, 𝐬𝐨 𝐬𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐩𝐥𝐚𝐜𝐞 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤 𝐭𝐨 𝐬𝐚𝐯𝐞 𝐮𝐩 𝐭𝐨 $𝟖𝟓𝟎. See the full speaker line-up here - https://lnkd.in/edCgc8sg Register your place here - https://lnkd.in/e4JMEfKT If interested please get in touch with myself, Julia Lenkiewicz and Younis Aljebechi who can provide the relevant information and answer any questions. Looking forward to seeing as many of you in Boston next February! #adc #worldadc #antibodydrugconjugates

🔬 Exciting Milestone Alert! 🚀 Lifebit has just announced a groundbreaking achievement, having amassed RWE & Multi-Omics data from over 100 million patients globally. This milestone is not just a number—it's a testament to the power of data in transforming healthcare and pharmaceutical research. 🧬 Lifebit's extensive data catalog, encompassing RWE & Multi-Omics datasets for over 200 health conditions from more than 30 data partners, represents the world's most diverse genomic and health data resources. This diversity is crucial for pharma, as it enables a deeper understanding of diseases and accelerates the development of targeted therapies. 🌍 The coverage of critical disease areas, including cancer, cardiovascular, respiratory, neurological, diabetes, and rare diseases, underscores the potential of this data to tackle the most significant threats to human health. 💡 For my connections in pharma: This is an unparalleled opportunity to leverage Lifebit's data for your R&D efforts, driving innovation and advancing the frontiers of precision medicine. Their commitment to data diversity and accessibility is pivotal for our industry's future, enabling us to develop more effective, personalized treatments. #PrecisionMedicine #Biotech #DataInnovation #Lifebit #datasaveslives https://lnkd.in/e2udx-sZ

Want to learn more about novel formats and payloads being used to overcome limitations over traditional ADCs? Take a look at the 𝟑𝐫𝐝 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐂𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞𝐬 𝐒𝐮𝐦𝐦𝐢𝐭 event guide here: https://ter.li/gk21k3

That is great news (and somewhat overdue). As an academic clinician, I hope this FDA-Innovation Hub will look beyond the typical FDA/CBER/CDER missions and pay (a lot more) attention to two main bottlenecks in bringing advanced therapeutics to patients with rare diseases:   1] A contracting workforce of (academic) physicians that are, and will be (see ASGCT report), tasked with implementing these rare therapeutics.    https://lnkd.in/ehi8e79b   https://lnkd.in/e-FbPgDu   https://lnkd.in/eUP3Ez3j     2] General lack of implementation strategies by Sponsors (the “what happens now that the product is FDA-approved”). The FDA-Innovation Hub can help with harmonizing implementation strategies, encouraging Sponsors to share implementation plans with the FDA (before approval) and potential treatment centers, related, harmonized certification criteria for QTCs. Last, but not least, this FDA-Innovation Hub should play a greater role in the determination of value (and the payer side of the therapeutic supply chain).  

🔬 Exciting News for Microbiome Enthusiasts! 🔬 Join us at the premier Microbiome Meeting in the Europe and unlock unprecedented opportunities for your career and drug development pipelines! 🌐 🚀 Save up to 770 Euros on a pass if you register before 24th November! 🌟 https://ter.li/ouae04 This is your chance to connect with key industry leaders from Roche, Novartis, M Ventures , AOBiome Therapeutics, Inc., MaaT Pharma and more! 🤝 Event Highlights: - 🌍 The Premier European Microbiome Meeting: bringing together trailblazers from industry, academia, and investors - 🧬 Insights across various fields: explore ground-breaking insights in autoimmune disorders, oncology, lung disease, metabolic disease, women’s health, and more! - 🔄 New Interactive Sessions: experience a reverse pitch opportunity, technology showcase, poster session, and guided networking - 💡 Transformative Networking: meet like-minded individuals and industry experts to collaborate and propel your projects forward Don't miss out on this unmissable event that promises to revolutionize your approach to drug development! 💊 👉 Register Now and Unlock Savings: https://ter.li/ouae04 Seize the opportunity to revolutionize your drug development pipelines and build lasting connections with the pioneers of the microbiome movement. See you there! 🌐🔬 #Microbiome #DrugDevelopment #NetworkingOpportunity #InnovationInTheLab #MicrobiomeMovement #BiotechRevolution

Seoul, South Korea, July 30, 2024 – Lmito Therapeutics announced today that, effective June 1, 2024, it has become a member of Johnson & Johnson Innovation – JLABS Korea. The company is working toward developing novel therapies for immunological disorders through an emerging concept of metabolic reprogramming. Lmito's innovative technology focuses on modulating immunometabolism within the inflammation microenvironment (IME). This approach has demonstrated potential in promoting anti-inflammatory responses while also reducing fibrosis, offering a dual-action solution. By addressing these critical aspects of disease progression, Lmito aims to develop more effective and safer treatments for patients with chronic inflammatory and fibrotic conditions concurrently. "We are thrilled to join as an inaugural member of JLABS Korea as it marks a significant milestone in Lmito's journey," remarked Wheeseong Lee, CEO of Lmito. "The JLABS network will provide us with world-class mentorship and invaluable resources and research capabilities to accelerate Lmito's innovative approach in developing therapies for a spectrum of autoimmune diseases." The company's membership of JLABS Korea will leverage the expertise and global reach of Johnson & Johnson and the track record of JLABS in accelerating innovation across the globe. We aim to connect within innovative circles and create pathways to potential pharmaceutical industry partnerships, positioning Lmito at the forefront of biotechnological advancement. About Lmito: Lmito is a biotechnology company pioneering the modulation of cell metabolisms in the inflammation, fibrosis, and tumor microenvironments to develop innovative therapies for autoimmune diseases, fibrosis, and cancer, respectively. This innovative strategy targets critical aspects of various chronic diseases, addressing the pressing need for more effective treatments with fewer side effects in multiple conditions. By leveraging its expertise in metabolic reprogramming, Lmito aims to transform the treatment landscape for patients with limited therapeutic options. https://lnkd.in/gKk9ypDp.

Impressive progress in AI-driven drug discovery showcases the dynamic growth of this sector. Rejuve.Bio is inspired by such advancements and is focused on integrating Advanced AI for groundbreaking longevity drug discovery, enhancing healthspan and addressing aging-related diseases. https://lnkd.in/g_Gvu_nq